For Forest, one Bystolic test down, six to go

Share this article:

Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others seeking to market BP med Bystolic before its patent runs out.

Forest and Indian generics firm Hetero announced they reached a deal under which Hetero wouldn't launch its Bystolic copy until three months prior to the expiration of the med's ‘040 patent -- which would be in late 2021 -- or when Hetero receives FDA sign-off of its ANDA, whichever comes later. The deal follows submission by the parties of a joint stipulation and order to dismiss their patent case.

The settlement gets Forest closer to locking up exclusivity on Bystolic through 2016, say analysts. “We view clarity on this critical issue as a favorable first step toward resolving FRX's greatest uncertainty,” wrote Leerink Swann's Seamus Fernandez wrote in an investor note.

In practice, though, the settlement has little impact on what Fernandez calls Forest's “Bystolic overhang.” Six other players including Watson, have filed ANDAs, meaning patent infringement litigation with those filers remains in the courts. Forest must settle with all parties to fully resolve the Bystolic challenge.

That's not such a long shot. As Leerink points out, Forest successfully executed a multi-party settlement on Alzheimer's drug Namenda with 11 generic challengers, who had sought to market copies of the drug before its scheduled loss of exclusivity in 2015.

Forest is hurting from the 2012 patent expiration of depression med Lexapro, but COPD drug Tudorza (aclidinium) and IBS drug Linzess (linaclotide) were both approved this year, and the company's portfolio includes other potential new drugs including antipsychotic cariprazine and antidepressant levomilnacipran.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...